Skip to main content
. 2015 Jan;35(1):45–50. doi: 10.1177/0333102414542290

Figure 2.

Figure 2.

Percentage of patients pain free two hours after administration of frovatriptan (Frova), FroDex25 or FroDex37.5 in the 76 female with menstrually related migraine (MRM). Asterisks indicate a statistically significant difference (p < 0.05) between the group treated with Frova alone and the group treated with FroDex37.5. FroDex: frovatriptan plus dexketoprofen.